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Abstract: Metalloaminopeptidases (mAPs) are enzymes that are involved in
HIV infectivity, tumor growth and metastasis, angiogenesis, and bacterial
infection. Investigation of structure-function relationships in mAPs is a
prerequisite to rational design of anti-mAP chemotherapeutics. The most
intensively studied member of the biomedically important dinuclear mAPs is
the prototypical secreted Vibrio proteolyticus di-zinc aminopeptidase (VpAP).
The wild-type enzyme is readily purified from the supernatant of cultures of
V. proteolyticus, but recombinant variants require expression in Escherichia
coli. A greatly improved system for the purification of recombinant VpAP is
described. A VpAP-(His)6 polypeptide, containing an N-terminal propeptide,
and a C-terminal (His)6 adduct, was purified by metal ion affinity
chromatography from the supernatant of cultures of E. coli. This single step
replaced the sequence of (NH4)2SO4 fractionation, and anion exchange and
hydrophobic interaction chromatographic separations of earlier methods.
Traditionally, recombinant VpAP proenzyme has been treated with proteinase
K and with heat (70 °C), to remove the N- and C-terminal regions, and yield
the mature active enzyme. This method is unsuitable for VpAP variants that
are unstable towards these treatments. In the new method, the hitherto
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noted, but not fully appreciated, ability of VpAP to autocatalyze the hydrolysis
of the N-terminal propeptide and C-terminal regions was exploited; extensive
dialysis of the highly purified VpAP-(His)6 full-length polypeptide yielded the
mature active protein without recourse to proteinase K or heat treatment.
Purification of variants that have previously defied isolation as mature forms
of the protein was thus carried out.

Introductory Statement
Metalloaminopeptidases (mAPs) are key players in many
biological processes, including cellular targeting of proteins [1, 2],
protein degradation [1, 3, 4], aging [5-10], tissue repair [11-15],
cataract formation [16-22], HIV infectivity [23-26], angiogenesis [2731], and carcinogenesis [27, 32-34]. A biomedically important family
of mAPs is that of the dinuclear mAPs, also known as “cocatalytic”
mAPs [35]. The dinuclear mAPs hydrolyze the N-terminal amino acid
from peptides and proteins, with varying degrees of substrate
specificity, and are characterized by an active site that contains two
transition ions, usually Zn(II), separated by about 0.35 nm (3.5 Å) in a
dinuclear active site. The most intensively studied and well
characterized of these enzymes is the 32kD secreted di-zinc leucine
aminopeptidase, VpAP, from Vibrio proteolyticus (formerly Aeromonas
proteolytica) [36-40]. It appears that one of the metal ions in VpAP
and related mAPs is involved in nucleophile activation, and is essential
for catalysis, whereas the other is involved in substrate activation and
stabilization of the transition state [36, 39, 41]; the non-essential
metal ion may thus be key to substrate specificity, though conclusive
evidence is lacking. Other dinuclear mAPs that have been studied
include the angiogenesis target methionyl aminopeptidase, and the
secreted aminopeptidases that are virulence factors in the
pathogenicity of certain species of Clostridium, Streptomyces, Vibrio
and Aeromonas [42-48]. VpAP itself exhibits a very high degree of
structural homology with the protease domain of the prostate-specific
membrane antigen (PSMA) [49]. PSMA is highly expressed in prostate
cancer cells [50], but its role in prostate cancer is currently unknown.
Some potent inhibitors of VpAP and its homologs, including bestatin
(ubenimex), ovalicin, and fumagillin, have also been shown to exhibit
in vivo activity against tumor growth, angiogenesis, and HIV infectivity
[8, 24, 51-59]. Wild-type VpAP is readily available in large quantities
from V. proteolyticus, and it is an excellent model protein with which
to explore the structure-function relationships of mAPs: studies on
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VpAP have provided information that may lead to the design of more
effective and specific chemotherapeutic agents [35, 39-41, 60].
However, recent work on VpAP and VpAP homologs has shown that
site-directed recombinant variants can provide important mechanistic
information that is unavailable with the native proteins [61-64]. A
need exists, therefore, for an efficient expression system and
purification protocol for recombinant VpAP that can provide sufficient
quantity of high-purity material for physicochemical, structural, and
spectroscopic study of site-directed variants of VpAP.
VpAP has been isolated from cultures of V. proteolyticus since
the mid-1960s. Investigation of the proteolytic activity associated with
V. proteolyticus [65] led to the identification and isolation of VpAP by
Prescott and Wilkes [66]. Subsequent refinements of the purification
procedure [67, 68] resulted in a protocol that yielded VpAP
preparations that were sufficiently homogenous for crystallization. The
purification of VpAP is complicated by the fact that the 32 kDa mature
active protein is the product of substantial processing of a 54 kDa
translated polypeptide, VpAP*, coded for by the native ORF [69, 70].
The 54 kDa VpAP* polypeptide consists of a 21 amino acid signal
peptide, an 85 amino acid N-terminal propeptide, a 299 amino acid
mature region, and a 99 amino acid C-terminal propeptide (Figure 1).
The signal peptide is required for secretion, the N-terminal propeptide
is required for folding but its presence inhibits catalytic activity, and
the C-terminal propeptide is of undetermined function but appears to
be species-specific [71, 72]. VpAP* is processed to the final 32 kDa
mature protein only after secretion and during purification; roles in the
processing of VpAP* have been proposed for VpAP* itself (and VpAP)
in autoprocessing, for a co-expressed neutral protease, and for a heattreatment step that has been traditionally employed [73-75]. An
additional problem in the purification of VpAP for spectroscopic studies
is the presence of two low Mr (< 2kD) brown pigments, one of which
contains spectroscopically active Fe(III), that appear to be closely
associated with VpAP; any successful protocol must separate these
pigments from VpAP [76].
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Figure 1. Linear representations of various VpAP species. VpAP* is the native
polypeptide secreted by V. proteolyticus. ΔspΔCVpAP* is the polypeptide secreted by
E. coli expressing a construct of VpAP lacking the C-terminal polypeptide.
ΔspΔCVpAP*(His)6 is the polypeptide secreted by E. coli containing a plasmid that
included the new construct described herein. N-terminal processing of
ΔspΔCVpAP*(His)6 yields ΔNΔCVpAP*(His)6, and subsequent C-terminal processing
yields the mature VpAP polypeptide. The experimentally observed N-terminal
sequences are shown. The N-terminal sequence of natively expressed mature VpAP is
MPPI. Proteinase K treatment of recombinant VpAP* yielded a final N-terminal
sequence of ASFVMPPI, whereas autoprocessing resulted in an N-terminal sequence of
TLASFVMPPI. “N-pro-p.” and “C-pro-p.” denote the N- and C-terminal propeptides,
respectively, and “s.p.” denotes a signal peptide.

The commonly and successfully used protocol for the purification
of VpAP from V. proteolyticus involves (i) rapid separation of the
supernatant from V. proteolyticus cells; (ii) (NH4)2SO4 fractionation of
the supernatant; (iii) heat treatment (70 °C for 5 – 7 h), followed by
dialysis and clarification by centrifugation and filtration (0.22 μm); (iv)
one or two hydrophobic interaction chromatographic fractionations
(octyl-Sepharose); and (v) anion-exchange chromatography (QSepharose). A highly detailed investigation into the requirements for
the isolation of VpAP heterologously expressed in E. coli has been
described by Bzymek, Holz and coworkers [71], and the resulting
protocol has yielded both recombinant wild-type and site-directed
variant forms of VpAP for subsequent crystallographic and
physicochemical studies [38, 61-63, 71]. As suggested by earlier work
[72, 77-79], it was found that VpAP was best expressed as a 52 kDa
proenzyme (ΔspVpAP*; lacking the first 23 amino acids); the use of an
appropriate leader sequence (e.g. the pelB sequence of pET26b(+))
results in secretion of the proenzyme, which can be purified from the
supernatant. Essentially the same purification procedure as for the
native enzyme from V. proteolyticus was adopted, except for an
additional incubation with proteinase K (PK), which appears to mimic
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the effects of V. proteolyticus neutral protease and removes the Nterminal propeptide, prior to heat treatment.
In the course of our own studies, we have followed the earlier
procedure [71] for the purification of recombinant wild-type and
variant VpAP and have successfully isolated VpAP with amino acid
substitutions in the active site pocket and in an adjacent hydrophobic
pocket [39]. However, we have also encountered problems, including
(i) irreproducible, and generally low, yields of VpAP; (ii)
unpredictability of the effects of PK on variant forms of VpAP*; and
(iii) the inability to isolate some site-directed variants as the mature
proteins, notably variants with substitutions of Asp99. In the present
work, we describe a rapid purification scheme for heterologously
expressed VpAP that reproducibly yields 10 mg of pure wild-type VpAP
per liter of E. coli culture. In addition, we describe the expression and
purification of the D99A, D99H, and D99M variant forms of VpAP, that
had hitherto defied isolation as mature proteins. The advantages of the
new method are discussed.

Materials and Methods
General chemicals and reagents
Restriction enzymes, T4 DNA ligase, and Antarctic phosphatase
were purchased from New England Biolabs (Ipswich, MA). A dNTP
cocktail and Pfu Turbo polymerase were purchased from Stratagene
(La Jolla, CA). BL21 Star DE3 One Shot Chemically Competent E. coli
cells were purchased from Invitrogen (Carlsbad, CA). LB medium and
kanamycin were purchased from Fisher Scientific (Fair Lawn, NJ). IPTG
was obtained from Anatrace Incorporated (Maumee, OH), aliquoted
into 1 ml volumes of 1 M concentration, and stored at −20 °C until
use. Pre-cast PAGE gels were purchased from BioRad Laboratories
(Hercules, CA). Agarose bead-linked proteinase K from Tritirachium
album was purchased from Sigma-Aldrich (St. Louis, MO). All other
general chemicals (ACS grade) and buffer salts (Biotech or
electrophoresis grade) were obtained from Sigma-Aldrich (St. Louis,
MO). Deionized water was additionally filtered for organic and metal
ion contaminants using a Milli-Q system (Millipore, Molsheim, France)
and exhibited a resistance of > 18 MΩ.
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Plasmids
cDNA was amplified by PCR from the plasmid pVSNMC [72],
obtained from the Applied Enzymology Laboratory of the National Food
Research Institute (Ibaraki, Japan), using the forward and reverse
primers 5′-GGCTTCCATGGAAGACAAAGTGTGGATCTCA-3′ (forward;
NcoI site underlined), and 5′-GCGCGCCTCGAGCTGATTGCC-3′
(reverse; XhoI site underlined). The PCR product was then inserted
between the NcoI and XhoI sites of pET26b(+) (Invitrogen, Carlsbad,
CA). The reverse primer lacked the VpAP native stop codon, thus
transcription continued through the (His)6-coding sequence
immediately downstream of the XhoI site in pET26b(+), and was
stopped immediately after (His)6. The resulting construct, pAPMH, was
used to express a wild-type polypeptide (ΔspΔCVpAP*(His)6)
containing the N-terminal propeptide, the mature VpAP polypeptide,
and a C-terminal (His)6 construct, but lacking the signal sequence and
the C-terminal propeptide. pAPMH was also used as the template to
generate VpAP site-directed variants.
Recombinant DNA for the D99A, D99M, and D99H variants of VpAP
was generated using the following primers (mutations underlined):
D99A forward, 5′-GGTGGTCACCTTGCTTCGACCATTGGTTCAC-3′;
D99A reverse, 5′-GAACCAATGGTCGAAGCAAGGTGACCACC-3′;
D99M forward, 5′-GGTGGTCACCTTATGTCGACCATTGGTTCACAC-3′;
D99M reverse, 5′-GTGTGAACCAATGGTCGACATAAGGTGACCACC-3′;
D99H forward, 5′-GGTGGTCACCTTCATTCGACCATTGGTTCACAC-3′;
D99H reverse, 5′-GGTGGTCACCTTCATTCGACCATTGGTTCACAC-3′.
A six-step PCR protocol was employed with the following parameters:
step 1, 95 °C for 1 min; step 2, 95 °C for 30 s; step 3, primer Tm −
10 °C, 1 min; step 4, 68 °C for 8 min; step 5, 18 cycles of steps 2 – 4;
step 6, 68 °C for 10 min.
All constructs were fully sequenced (Applied Biosystems ABI
PRISM 3100 analyzer, Protein and Nucleic Acid Facility, Medical College
of Wisconsin, Milwaukee, WI) and found to contain no mutations
except for those intended. Sequence-verified constructs were used to
transform BL21 Star (DE3) One Shot Chemically Competent E. coli
cells (F- ompT hsdSB (rB-mB-) gal dcm rne131 (DE3)), using the
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transformation protocol provided by the manufacturer (Invitrogen,
Carlsbad, CA). Frozen stocks were prepared by adding 1 ml bacterial
culture (OD600 nm ≈ 0.6) to 1 ml 30% glycerol (in water), snap frozen
in liquid nitrogen, and stored at −80 °C.

Expression of VpAP
Starter cultures were prepared by inoculation of 20 ml LB,
containing 30 μg/ml kanamycin, with a scraping from frozen stock
cultures, followed by agitation at 250 rpm, 37 °C, in a 50 ml conical
tube, until the OD600 nm reached 1.0. Cultures for VpAP expression were
prepared by adding 2.5 ml of starter culture to a 1 L flask containing
250 ml LB (30 μg/ml kanamycin). Flasks were agitated in an orbital
shaker at 250 rpm, 37 °C until OD600 nm = 0.6. IPTG was added (to a
final concentration of 1 mM), and flasks were further agitated for 18 h,
250 rpm, 30 °C.

Assay of VpAP
Steady state VpAP activity was estimated from
spectrophotometric determination of the rate of formation of the
product, p-nitroaniline (PNA), of hydrolysis of L-leucine-p-nitroaniline
(LPNA; Sigma, St. Louis, MO), at 405 nm, 25 °C. The assay mixture
contained 1.0 mM LPNA in 10 mM Tricine buffer, pH 8.0 [67, 80] and a
differential extinction coefficient Δε405 nm = 10,800 M-1 cm-1 was
employed [81]. A “Unit” of activity was defined as a rate of hydrolysis
of 1 μmol LPNA min-1 under these conditions. Apparent kinetic
parameters K′m and k′cat were estimated by collecting the entire
progress curve, with initial [LPNA] = 0.1 mM, and fitting the part of
the curve that exhibited a linear relationship between t-1[ln([S0]/[St])]
and t-1[S0 − St] [39, 82]. This approach indicated that the steady state
assay routinely underestimated Vmax by a factor of 1.3, likely because
of weak substrate inhibition, but steady state values were determined
for wild-type VpAP for comparison to other studies. Quantities of
ΔspΔCVpAP*(His)6 were estimated spectrophotometrically, taking ε280
-1
cm-1, and purified mature VpAP protein was estimated
nm = 58,110 M
taking ε280 nm = 43,950 M-1 cm-1 [76, 83-85]. SDS-PAGE analysis was
carried out on precast 4 - 15 % polyacrylamide/Tris-HCl gels (BioRad
“Ready Gels”). Samples of VpAP were generally loaded directly onto
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SDS-PAGE gels without pretreatment. Occasionally, samples were
heated for 5 min at 95 °C in the presence of either 33 mM
dithiothreitol, 66 mM β-mercaptoethanol, or both, prior to SDS-PAGE
analysis. These pretreatments were found to diminish the intensities of
bands showing anomalously high apparent Mr, but did not affect the
number or the positions of the bands. SDS-PAGE analyses presented
herein were carried out on samples that had not been pretreated,
except where explicitly stated in the figure legend (i.e. only Figure 4).

Figure 4: Time dependence of incubation with proteinase K on the apparent Mr of
VpAP. Lane 1, Recombinant VpAP prior to proteinase K exposure; Lane 2, after further
incubation (90 min) with proteinase K; Lane 3, Mr markers. (β-mercaptoethanol and
dithiothreitol were employed in the sample buffers).
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Purification of wild-type VpAP
Step A: Cultures were clarified by centrifugation (5200 × g, 10 min,
4 °C), and 1 L supernatant was applied (3.0 ml/min, 4 °C) to 15 ml
TALON Superflow Metal Affinity Resin (Clontech, Mountain View, CA).
The resin was washed with 75 ml of 50 mM HEPES buffer, pH 7.5, at
1.0 ml/min. HEPES buffer (50 mM, pH 7.5), containing imidazole (20
mM), was applied (3.0 ml/min) to effect protein elution. Fractions (6
ml) were assayed for activity and protein content. In order to speed
future identification of fractions containing site-directed variants of
VpAP that may show no detectable activity, the retention volumes for
the fractions of wild-type VpAP with highest specific activity were
characterized from the commencement of application of imidazole.
Fractions containing protein and expressing VpAP activity were
combined and dialyzed at 4 °C against 50 mM HEPES buffer, pH 7.5,
to dilute imidazole to a final concentration of < 1 nM.

Step B: The dialysate from Step A was agitated (250 rpm, 37 °C) with
≈ 5 mg (≈ 0.025 units; ≈ 1 μg protein equivalent) PK agarose beads.
Aliquots were periodically assayed for VpAP activity toward LPNA.
When the activity toward LPNA ceased to increase upon further
incubation with PK (generally ≈ 40 min), the VpAP-containing
suspension was filtered to remove the PK beads (0.22 μm, Millipore
mixed cellulose esters [MCE] syringe filter).

Step C: The solution from Step B was immediately incubated at 70 °C
in a water bath, either until the activity began to decrease, or else for
1 h. The suspension was cooled on ice, filtered (0.22 μm), and
dialyzed (50 mM HEPES, pH 7.5, 4 °C).

Step D: The solution from Step C was applied (2.0 ml/min, 4 °C) to a
15 ml TALON Co(II)-affinity resin column. HEPES buffer (50 mM, pH
7.5) was applied, and eluate fractions that contained the highest
specific activity toward LPNA were pooled and concentrated by
ultrafiltration (Amicon PM10). As in Step A, retention volumes were
characterized.
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Purification of VpAP D99-substituted variants D99A,
D99H and D99M
Step A was carried out as for wild-type VpAP. Because the
activities of the D99-substituted variants were extremely low at this
stage, fractions were collected using the retention volumes
characterized for wild-type. Protein content was estimated from A280
nm. Steps B and C, however, were replaced by Step E, which entailed
extended (7 – 14 d) dialysis against HEPES buffer (50 mM, pH 7.5) at
4 °C. Self-processing of VpAP D99-substituted variants was monitored
by SDS-PAGE on 4 – 20 % polyacrylamide gradient gels. When SDSPAGE and N-terminal amino acid sequencing indicated complete
processing, the dialysate was filtered (0.22 μm), and further processed
as described for Step D for wild-type VpAP. The previously
characterized retention volumes for wild-type VpAP were used as an
aid to identifying fractions containing VpAP D99-substituted variants.

N-terminal amino acid sequencing
Proteins were separated on SDS-PAGE gels, transferred to
polyvinylidene fluoride membranes, excised, and N-terminal
sequenced by Edman degradation using a Beckman Porton LF3000G
sequencer with in-line Applied Biosystems PTH analyzer, at the Protein
and Nucleic Acid Core Facility at the Medical College of Wisconsin.

Circular dichroism spectropolarimetry
Circular dichroism spectra were recorded at 25 °C using a
JASCO J-710 spectropolarimeter equipped with a 1 mm path-length
quartz cell. Samples for spectropolarimetry were equilibrated with 5
mM phosphate buffer, pH 7.5, by dialysis.

Crystallization of heterologously expressed VpAP
VpAP was crystallized from a hanging drop. VpAP (0.5 mM) in
10 mM Tris buffer, pH 8.0, containing 10 mM KSCN and 400 mM NaCl
was equilibrated with 100 mM Tris buffer, pH 8.0, containing 100 mM
KSCN and 4.5 M NaCl, at 19 °C.
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X-ray diffraction
Diffraction data were collected on a single crystal of
heterologously expressed wild-type VpAP, with Paratone-N (Hampton)
as a cryoprotectant, at −160 °C on a Rigaku R-AXIS IV++
diffractometer using Crystal Clear software [86]. An oscillation step
size of 1.0° was used to collect 3 min exposures. Data were processed
and unit cell parameters determined with HKL2000 [87]. Phases were
derived from a structure previously solved in this laboratory (accession
code 2IQ6 [88]) and used to solve the structure by molecular
replacement using Phaser [89]. Model building was performed with the
graphic program COOT [90]. The structure was manually inspected
with electron density maps and with 2Fobs − Fcalc and Fobs − Fcalc
coefficients. Structures were refined using iterative cycles of energy
minimization using REFMAC5 [91] in the CCP4 program suite [92],
alternating with manual map-fitting and model rebuilding. Progress of
the refinement was confirmed by the steady decrease in both the
Rcrystal and Rfree values. Procheck was used to check Ramachandran (φ,
ψ) values [93].

Results
Expression and purification of wild-type VpAP
10 L of E. coli culture, OD600 nm = 2.3, yielded 20 g wet weight of
cells, which were discarded. Up to 10 mg of wild-type VpAP, with a
steady state ([LPNA] ≈ 1 mM) specific activity of 120 Units/mg at
25 °C, was purified from the supernatant. The purification of wild-type
VpAP is summarized in Table 1. Kinetic analysis indicated apparent
Michaelis-Menten parameters k′cat = 82 ± 2 s-1, and K′m = 18 ± 1 μM.
Table 1: Purification of wild-type VpAP
Purification step

Volume
(ml)

Total protein
(mg)

Activity
(Units)

Specific activity
(Units/mg)

Supernatant clarification

10,000

120,000a

320

0.003a

Step A

20

80

480

6

Steps B and C

20

68

7480

110

Step D

40

60

7200

120

aVpAP

was purified from the supernatant of bacterial cultures grown in LB medium,
that originally contained about 12 g/L of a mixture of peptides, peptones and proteins.
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Step A: VpAP-containing fractions that eluted during Co(II)-affinity
chromatography upon the application of imidazole were characterized
by three bands on SDS-PAGE, at apparent Mr ≈ 57 kDa, ≈ 42 kDa, and
≈ 32 kDa (bands A, B, and C of Figure 2). The relative intensities of
the bands appeared to be the same for each fraction. The origin of the
the “57 kDa” band, A, is unclear, as the cDNA coded for the 42kD
ΔspΔCVpAP*(His)6 polypeptide, but that material evidently bound the
Co(II) affinity resin with an affinity comparable to that for the material
responsible for the other two bands. N-terminal amino acid sequencing
of the other two bands, B and C, indicated the same N-terminal
sequence of EDKVWI for each, corresponding to the N-terminal region
of the 85 amino acid N-terminal propeptide, and these bands were
only observed in fractions that eluted upon the application of
imidazole, so contain the (His)6 adduct. Despite the apparent Mrs from
SDS-PAGE, then, both bands B and C must be due to
ΔspΔCVpAP*(His)6. The specific activity of the material following Step
A was ≈ 6 Units/mg, consistent with the retention of the inhibitory Nterminal propeptide in > 95 % of the polypeptide molecules.

Figure 2: SDS-PAGE analysis of Co(II)-affinity resin chromatographic fractionation of
wild-type VpAP-induced E. coli culture supernatant. Lane 1, Mr markers (pre-stained
Novex Sharp, Invitrogen; note that the band between 40 kDa and 60 kDa is 50 kDa);
Lane 2, Flow-through during application of supernatant; Lane 3, Flow-through during
washing with HEPES buffer; Lanes 4 - 6, Eluate upon application of imidazolecontaining buffer.
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The anomalous behavior of VpAP on SDS-PAGE is worthy of
comment. The apparent Mr of proteins from SDS-PAGE can be very
sensitive to even very minor differences in physicochemical properties
of polypeptides in some cases [94, 95]. Here, the origin of the
anomalous behavior on SDS-PAGE is unknown, but may be related to
the presence of cysteines with the potential to form disulfide bonds.
Mature VpAP contains only two cysteines, Cys223 and Cys227, that
form a disulfide bond. Larger recombinant constructs, however,
contain up to three additional cysteines; one is in the N-terminal
propeptide, and two reside in the C-terminal propeptide. The
ΔspΔCVpAP*(His)6 construct contains three cysteines. It is highly
likely, given the thermostability of VpAP, that the Cys223-Cys227
disulfide bond is very stable and that neither of these cysteines forms
a disulfide bond with the third cysteine in any significant fraction of the
sample. It is, however, possible that the cysteine that resides on the
N-terminal propeptide engages in intermolecular disulfide bond
formation. The presence of the N-terminal propeptide inhibits activity
and so likely is adjacent to the active site in the folded polypeptide;
given the extensive secondary structure and hydrophobic surface of
VpAP, dimers thus formed would likely be of high stability and possibly
partially resistant to SDS, leading to incomplete unfolding and the
presence of multiple bands. In SDS-PAGE analysis of VpAP after Step
A, pretreatment of samples by heating with β-mercaptoethanol and/or
dithiothreitol was found to diminish the intensity of the “57 kDa” and
“42 kDa” bands somewhat, but not completely. The thermostability of
VpAP (see Step C) may be related to this phenomenon. An additional
factor that may contribute to the anomalous behavior of unprocessed
and partially processed VpAP on SDS-PAGE is the presence of regions
of high hydrophobicity in both the mature VpAP sequence [96], and,
particularly, in the N-terminal propeptide.
Steps B and C: SDS-PAGE comparison of the material from Step A
(Lane 2, Figure 3) with those from Steps B (Lane 3, Figure 3) and C
(Lane 4, Figure 3) shows clear differences. Treatment with PK yielded
a dominant species with an apparent Mr of 32 kDa, and some minor
species of higher and lower apparent Mr. In contrast to results from
Step A, N-terminal sequencing of the major band from Step B returned
ASFVMP, indicating loss of the N-terminal propeptide [71]; the Nterminal region of mature natively-expressed VpAP begins MPPI, and is
preceded in this recombinant protein by ASFV from the C-terminal
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sequence of the N-terminal propeptide. The specific activity of ≈ 110
Units/mg was consistent with removal of the N-terminal propeptide.
More extensive incubation with PK (> 1 h) yielded a species with an
apparent Mr of 28 kDa, with no change in catalytic activity (Figure 4).
Two bands with apparent Mr of 28 and 32 kDa are routinely observed
with preparations of natively-expressed VpAP, and mass spectrometry
has indicated that the two bands correspond to species with almost
indistinguishable Mrs of 32 ± 1 and 31 ± 1 kDa [71]. Further
processing of PK-treated VpAP by heat treatment (i.e. Step C) yielded
a single species that was indistinguishable on SDS-PAGE (Lane 4,
Figure 3) or by Co(II)-affinity resin binding behavior (Figure 5) from
the major species observed prior to heat treatment; heat treatment
served to denature fragments that had been cleaved upon PK
treatment. In addition, following Step C, it was observed that the VpAP
activity could be recovered from Co(II)-affinity resin with HEPES
buffer, in the absence of imidazole, indicating that the C-terminal
(His)6 region was no longer present following Steps B and C. The
specific activity of 120 Units/mg for VpAP from Step C does not, in
fact, indicate any enhancement of the activity per mole upon heat
treatment, but reflects the removal of the cleaved N-terminal
propeptide, about 60 % of which appeared to have denatured during
PK-treatment and dialysis, and was removed by centrifugation, and
the remainder of which was denatured by heat treatment.

Protein Expression and Purification, Vol. 66, No. 1 (July 2009): pg. 91-101. DOI. This article is © Elsevier and permission
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

14

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Figure 3: Effects on SDS-PAGE analysis and N-terminal sequence of incubation with
proteinase K and heat treatment on Co(II)-afinity resin-fractionated wild-type
ΔspΔCVpAP*(His)6. Lane 1, Mr markers; Lane 2, Co(II)-afinity resin-fractionated
ΔspΔCVpAP*(His)6; Lane 3, ΔspΔCVpAP*(His)6 fraction (Lane 2) incubated with
proteinase K until maximum activity was reached; Lane 4, subsequent heat treatment
of material from Lane 3. Band X (Lane 2) returned an N-terminal sequence EDKVWI;
Bands Y and Z (Lanes 3 and 4, respectively) returned ASFVMP.

Figure 5: Fractionation of VpAP at various stages of processing by Co(II)-affinity
resin. Wild-type ΔspΔCVpAP*(His)6 obtained by Co(II)-affinity resin fractionation was
re-applied to Co(II)-affinity resin without further treatment (Lanes 1 - 5), after
incubation with proteinase K (Lanes 7 - 11), and after proteinase K and heat
treatment (Lanes 13 - 17). Fractions were collected during application of the sample
(“Flow-through”, Lanes 1, 7 and 13), during washing with HEPES buffer (Lanes 2, 3, 8
and 14), and upon application of imidazole-containing buffer (Lanes 4, 5, 9 - 11 and
15 - 17), and analyzed by SDS-PAGE. Mr markers are shown in Lanes 6 and 12.
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Step D: The purpose of Step D was to separate any VpAP that had not
had the C-terminal (His)6 removed during Step B and had yet
remained undenatured during Steps B and C. SDS-PAGE analyses
(Figure 5) indicated that no detectable amount of protein eluted from
the Co(II)-affinity resin upon the application of imidazole.

Expression and purification of VpAP:D99X variants
10 L E. coli cultures, OD600 nm = 2.0 - 2.3, yielded 15 - 20 g wet
weight of cells, which were discarded. From 1 to 2.5 mg of the D99substituted variants of VpAP were purified from the supernatants.
Steady state activities towards LPNA were significantly lower than for
wild-type VpAP: the activities of VpAP:D99M, VpAP:D99H and
VpAP:D99A were 0.030 ± 0.002, 0.004 ± 0.001, and 1.5 × 10-4 to 3.5
× 10-4 Units/mg, respectively. The purification of VpAP:D99M is
summarized in Table 2. Apparent kinetic parameters of k′cat = 1.0 ±
0.1 min-1, and K′m = 31 ± 7 μM were estimated from kinetic analysis
of VpAP:D99M; meaningful values for K′m could not be obtained for the
other variants due to the very low activities.
Table 2: Purification of VpAP:D99M
Purification step

Volume
(ml)

Total protein
(mg)

Activity
(Units)

Specific activity
(Units/mg)

Supernatant clarification

10,000

120,000a

N.D.b

N.D.b

Step A

N.D.b

N.D.b

20

3

c

20

N.D.

N.D.

N.D.b

Step Ec

20

2.4

0.07

0.03

Step D

60

2

0.06

0.03

Step B

d

b

b

aVpAP

was purified from the supernatant of bacterial cultures grown in LB medium,
that originally contained about 12 g/L of a mixture of peptides, peptones and proteins.
b“N.D.” signifies none detected.
cStep B and Step E are alternative procedures; either Step B or Step E was carried
out, not both.
dStep D was carried out only on material from Step E, not from Step B.

Step A processing of supernatant containing
ΔspΔCVpAP:D99X*(His)6, where X = A, H or M, proceeded as for wildtype VpAP, except that no activity towards LNPA was detectable at
that stage. In addition, the apparent Mr of the bands that eluted from
the Co(II)-affinity resin upon application of imidazole differed slightly
from wild-type (SDS-PAGE of crude VpAP:D99A after Step A is shown
as lane 4 of Figure 6 and crude VpAP:D99M is shown as Lane 1 of

Protein Expression and Purification, Vol. 66, No. 1 (July 2009): pg. 91-101. DOI. This article is © Elsevier and permission
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

16

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Figure 7; compare with wild-type VpAP, lane 5, Figure 2). The
differences between the non-reducing SDS-PAGE profiles of wild type
VpAP and of the VpAP:D99X variants may be related to the cysteine
content, just as the cysteine content may be responsible for the
presence of multiple bands, some with Mr higher than the molecular
species present, in the first place. In wild-type VpAP, the Cys223Cys227 disulfide bond is very stable, as attested to by the
thermostability of VpAP. Asp99 is a key residue in a hydrogen bonding
network that involves active site residues; indeed, it is of interest
because of its possible structural and catalytic roles.

Figure 6: Sensitivity of VpAP:D99A to incubation with proteinase K, monitored by
SDS-PAGE analysis. Supernatant of E. coli culture expressing ΔspΔCVpAP:D99A*(His)6
(Lane 2) was applied to Co(II)-affinity resin. Non-binding material flowed through the
column in the absence of imidazole (Lane 3). ΔspΔCVpAP:D99A*(His)6 eluted with
imidazole (Lanes 4 and 5) and was subsequently incubated with proteinase K for 10 50 min (Lanes 6 - 10).
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Figure 7: Autoprocessing of VpAP:D99M during extended dialysis monitored by SDSPAGE analysis. Lane 1, ΔspΔCVpAP:D99A*(His)6-containing fraction that eluted from
Co(II)-affinity resin with imidazole; Lane 2, after 13 d dialysis against HEPES buffer at
4 °C; Lane 3, Mr markers.

The Cys223-Cys227 disulfide bond is also a key structural
feature of the active site. It is perhaps possible that some active site
local structure is preserved, even in the presence of SDS, in wild-type
VpAP during SDS-PAGE; it is noteworthy that mass spectrometry has
verified that purified, mature VpAP does not run on SDS-PAGE
corresponding to its correct Mr [71]. The local structure may not be so
preserved in VpAP:D99X variants, however; a hypersensitivity to PK
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and heat treatment are consistent with lower structural stability. In
that case, at least six bands may be expected on SDS-PAGE, three
dimeric species with intermolecular disulfide bonds between the Nterminal propeptide cysteine of one monomer and three monomeric
species with a single disulfide; note that the suspected proximity of
the N-terminal propeptide to the active site, suggested by the
inhibitory effect on activity, would facilitate intramolecular disulfide
bond formation between the N-terminal propeptide and either of
Cys223 or Cys227 if the Cys223-Cys227 disulfide bond itself were not
subject to additional stabilization. Further work that is outside the
scope of the current study is clearly necessary to fully understand the
behavior of VpAP polypeptide constructs on SDS-PAGE. However, there
is available information on (i) the Cys content of mature and
unprocessed VpAP constructs, (ii) the thermostability and stable
disulfide bond in mature wild-type VpAP, (iii) the structural relationship
between D99, the active site, and the disulfide bond, (iv) the much
lower structural stability of D99 mutants and (v) the anomalous
behavior on SDS-PAGE of purified, mature VpAP of massspectrometry-verified Mr. These data are consistent with, and suggest
a mechanism for, multiple bands on SDS-PAGE for unprocessed VpAP
constructs, a single band for purified VpAP, and a different and more
complex band profile for VpAP:D99X variants unprocessed polypeptide
constructs than for wild-type.
Upon treatment with PK (Step B), VpAP:D99A was rapidly
degraded. After 10 min, bands at 28, 30 and 32 kDa were observable
on SDS-PAGE, along with fragments of lower apparent Mr (lane 6,
Figure 6). After 30 – 40 min, however, these bands had disappeared
(lanes 8 and 9, Figure 6), and, after 50 min, no protein at all was
observable on the gel (lane 10, Figure 6).
The lengthy methods of either SDS-PAGE or measurement of
very low levels of activity are, obviously, impractical for real-time
determination of when to terminate Step B, and this procedure could
not be reliably or reproducibly employed to process
ΔspΔCVpAP:D99X*(His)6. Instead, the alternative procedure of
extended dialysis without PK, Step E, was employed. VpAP:D99M
displayed the same SDS-PAGE profile as VpAP:D99A, following Step A
(lane 1, Figure 7), and a similar sensitivity to PK treatment. However,
upon extended dialysis at 4 °C against HEPES buffer, the bands in the
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range of apparent Mr = 30 − 40 kDa, and Mr ≈ 62 kDa, lost intensity
and a band with apparent Mr ≈ 28 kDa emerged, corresponding to the
31 ± 1 kDa species characterized by mass spectrometry, until, after
13 d, only the band at Mr ≈ 28 kDa was observable (lane 2, Figure 7).
The N-terminal amino acid sequence of this species was found to be
TLASFVM, corresponding to the final six amino acids of the N-terminal
propeptide, and the N-terminal methionine of mature VpAP; this
confirmed that the N-terminus was autoprocessed during dialysis. Step
D, a second application to Co(II)-affinity resin, was then carried out.
SDS-PAGE analysis (Figure 8) clearly showed that VpAP:D99M isolated
from Step E did not bind to the resin and that, therefore, the Cterminal region had also been removed during Step E. Circular
dichroism spectropolarimetery of D99M yielded a spectrum
indistinguishable from that of the “32 kDa” form of wild-type
recombinant, fully active enzyme (Figure 9). If Mr for VpAP:D99M were
really 28 kDa, this could only correspond to the loss of a large Cterminal α-helix, given the experimentally obtained N-terminal
sequences, and the circular dichroism spectra would be expected to be
significantly different.
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Figure 8: Loss of (His)6 construct from VpAP:D99M. Lane 1, VpAP:D99M after
extended dialysis; Lane 2, Flow-through from Co(II)-affinity resin during application of
VpAP:D99M and washing with buffer; Lane 3, Eluate upon application of imidazole;
Lane 4, Mr markers. Lane 1 corresponds to 1.2 μg protein and Lane 2 corresponds to
0.3 μg protein (10 μl of the sample described in Table 2, in each case).
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Figure 9: Circular dichroism spectra of recombinant wild-type VpAP (solid line) and
VpAP:D99M (dashed line).

Crystallization and crystallography of wild-type VpAP
Wild type VpAP protein readily formed hexagonal crystals
(Figure 10) with a space group of P6122. The structure was determined
to a resolution of 1.95 Å (1 Å = 0.1 nm; PDB code 3F4H) and the
crystallographic data collection and refinement statistics are given in
Table 3. The protein fold was essentially identical to those structures
already published. For comparison, the present structure, 3F4H, and
an earlier structure, 1LOK [38], were superimposable (LSQMAN) with a
root mean square deviation of 0.120 Å in Cα position. The inter-Zn
distances were 3.40 Å (3F4H) and 3.45 Å (1LOK). The crystal structure
also provided information on the C-terminus of the fully processed
protein. The residues comprising the sequence MGSATG were all
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clearly identifiable from the electron density and, as with natively
expressed VpAP, only the short C-terminal sequence DTPTPGNQ could
not be inferred from X-ray diffraction. In addition, the pre-N-terminal
residues ASFV were not clear from the X-ray diffraction data. The
possible range of Mr for the crystallized recombinant VpAP is, then,
31,388 to 32,640 D (not including Zn).

Figure 10: Crystals of heterologously expressed VpAP.

Table 3: Crystallographic data and refinement statistics for VpAP structure
3F4H
Data collection
Resolution (Highest Resolution Shell) (Å)

50 - 1.95 (2.02 - 1.95)

Total Reflections

79269

Unique Reflections

23164

Completeness (%)

95.5 (97.7)

<I/(σI)>

11.6 (2.6)

Cell Dimensions

a = b = 108.4 Å, c = 93.5 Å; γ = 120°

Space Group

P6122

Rmerge

0.094 (0.420)
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Vm, Solvent Content

2.48 Å3 D-1, 50.4 %

Monomers in Asymmetric Unit

1

Refinement
Number of Protein Atoms

2236

Number of Water Molecules

150

Number of Bound Ligands

8

Number of Zn Atoms

2

Number of Na Atoms

2

Bav. Main Chain
Bav. Side Chain
Bav. Zn

(Å2)

(Å2)

Bav. Tris
Bav. Na

(Å2)

15.6
14.3

(Å2)

(Å2)

Bav. Water

14.9

(Å2)

19.6
11.1
17.7

Rcryst. / Rfree

0.191 / 0.229

R.M.S.D. Bond Length / Angle

0.009 Å / 1.138°

Ramachandran Plot
Most Favored

88.4 %

Additional Favored

11.2 %

Generously Allowed

0.4 % (Met180)

Discussion
VpAP has been extensively studied, because of its high
structural homology to many biomedically important
metallohydrolases, and because of the actual and potential clinical
utility of inhibitors of the enzyme [35, 36, 40]. In particular, the
mechanism of action of the enzyme is seen as providing a prototypical
template for the rational design of anti-cancer, anti-angiogenic and
antibiotic chemotherapeutic agents. Despite much elegant work on the
native wild-type enzyme, that has provided much insight into the
catalytic mechanism, questions remain; even the roles of the distinct
Zn(II) ions in the active site, once thought to be clear [60, 76, 97],
are now somewhat controversial [39, 98]. The focus of recent
structure-function research on VpAP, and on closely related enzymes,
has been on site-directed variants [61-64, 98], as these may provide
further insight into the structure-function relationships in VpAP.
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A prerequisite to structure-function studies on site-directed
variants of VpAP is a method by which these proteins can be
expressed and purified. The challenges associated with heterologous
expression and purification of VpAP are evident from earlier work, and
have been particularly thoroughly addressed in a report by Bzymek,
Holz and coworkers [71, 72]. Briefly, the problems include (i) the
desirability of a mechanism by which VpAP is exported from the cell, to
prevent inclusion body formation; (ii) the requirement for an Nterminal propeptide for correct folding; (iii) the inhibitory nature of the
N-terminal propeptide, which makes identification and quantitation of
unprocessed VpAP* by activity very difficult; (iv) anomalous behavior
of VpAP* on SDS-PAGE gels; (v) the need for aggressive treatment
with proteases and heat to process VpAP* to VpAP; (vi) multiple
lengthy and inefficient chromatographic separations. Despite these
challenges, Bzymek et al. were able to design a protocol for isolation
of heterologously expressed VpAP that yielded wild-type and some
site-directed variant forms of VpAP.
Despite the successes of the method of Bzymek, Holz and
coworkers, two outstanding issues led us to revisit the expression and
purification of VpAP from an E. coli expression system. The first was
that we were unable to isolate some site-directed variants using this
method. Where initial expression was low, the losses in terms of
recoverable material during the traditional chromatographic steps were
unacceptable. In addition, as our data clearly show, some variants
were so sensitive to proteinase K treatment, and the procedure so
difficult to control with variants exhibiting low specific activity, that
incubation with proteinase K could not be reliably used to cleave the
N-terminal propeptide. The second outstanding issue was that of final
purity of the product. Many site-directed variants of interest in
structure-function studies have very low activities compared to wildtype VpAP. Reported activities of e.g. 0.004 % of that of wild-type
have been reported [61]. Important mechanistic information is
available from kinetic studies of variants with even very low activities;
for instance, K′m informs on the ability of a kinetically compromised
variant to form a Michealis complex with substrate. However, these
studies rely on the level of contamination by other proteolytic enzymes
being extremely low, much lower than can be determined by SDSPAGE. While heat treatment may be expected to denature most
proteins other than VpAP, there is no analytical way to determine that
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heat treatment does indeed destroy all contaminating proteases to a
remaining level of ≪ 0.004 %. In addition, some VpAP site-directed
variants are unstable toward heat treatment as well as toward
proteinase K.
The expression of VpAP as a construct with a (His)6 adduct
facilitated a very rapid and effective first purification step. Three bands
were evident on SDS-PAGE after this first step; two of the bands were
shown to be due to ΔspΔCVpAP*(His)6, indicating anomalous behavior
on SDS. Given (i) the known propensity of both unprocessed and
processed VpAP to behave anomalously on SDS-PAGE, (ii) the
requirement of imidazole for elution of the unprocessed material from
the Co(II)-affinity resin, (iii) a constant ratio of the intensities of the
three bands among fractions from the Co(II)-affinity column, and (iv)
that a single product resulted from processing of the unprocessed
material, it is likely that all three bands were due to
ΔspΔCVpAP*(His)6. Earlier attempts to employ a “ΔC” construct, i.e.
one lacking 43 amino acids of the C-terminal propeptide (“pET27b(+)43AAP”), resulted in a processed product with only 35 % of the activity
of the native enzyme [71]. In contrast, processing of
ΔspΔCVpAP*(His)6, in which the entire C-terminal propeptide was
deleted, provided VpAP with activity as high as any reported and with
K′m in the range of typically reported values.
The use of a (His)6-containing construct allowed for rapid
purification of VpAP but presented the concern that the (His)6
construct may not be removed during processing. As VpAP is a
transition ion-dependent enzyme, structure-function studies
addressing the active site would be compromised by binding of metal
ions to the (His)6 sequence. In particular, Co(II) is commonly used as
a spectroscopically active substitute for the native Zn(II) but (His)6
has a relatively high affinity for Co(II). An important final step,
therefore, was the reapplication of fully processed VpAP to TALON
Co(II)-affinity resin, and only fractions that did not bind, under the
conditions that ΔspΔCVpAP*(His)6does bind, were retained. In
practice, no SDS-PAGE-detectable material was actually observed in
fractions collected upon subsequent application of imidazole, indicating
highly efficient cleavage. The specific site of cleavage is unclear, but
the crystal structure of wild-type VpAP indicated that it is somewhere
in the short C-terminal sequence DTPTPGNQLE that immediately
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precedes (His)6. The ready crystallization, and sub-2 Å X-ray
diffraction of the crystals, suggests a highly pure and homogeneous
final product.
The use of the (His)6 construct was also applied to VpAP
variants. One of the principal advantages was the rapid separation of
fragile variants, such as the VpAP:D99X family, from other proteolytic
enzymes. Studies with PK have shown these variants to be far less
resistant than wild-type VpAP to proteolytic action, and the one-step
Co(II)-affinity column isolation of ΔspΔCVpAP*:D99X(His)6 has
replaced much lengthier and less effective hydrophobic interaction and
anion exchange chromatographic steps that have been traditionally
employed. Key to the use of ΔspΔCVpAP*:D99X(His)6, however, was
the observation that solutions that had undergone exhaustive dialysis,
followed by filtration, did not bind to Co(II)-affinity resin when
reapplied. This observation suggested that ΔspΔCVpAP*:D99X(His)6
was capable of autoprocessing. Along with a role for a neutral protease
expressed by V. proteolyticus in processing VpAP*, autoprocessing by
VpAP has also long been suspected. However, as crude preparations
have not been free of other proteolytic activity, it has been difficult to
confirm such a role. In the case of the ΔspΔCVpAP*:D99X(His)6
variants, however, Co(II)-affinity resin chromatography provided a
highly purified species, notwithstanding the anomalous behavior on
SDS-PAGE. In addition to removal of the (His)6 adduct, exhaustive
dialysis was shown by SDS-PAGE, and earlier mass spectrometry
studies on wild-type VpAP, to have processed ΔspΔCVpAP*:D99X(His)6
to a single species with Mr = 31 kDa. This indicated removal of the Nterminal propeptide, and this was confirmed by N-terminal sequencing.
It was confirmed by circular dichroism spectropolarimetry that
extensive C-terminal processing did not occur, despite the apparent Mr
of 28 kDa from SDS-PAGE. The 3 - 4 kDa C-terminal region that would
have been lost from the 32 kDa protein to form a 28 kDa species
would consist almost entirely of α-helix, and the circular dichroism
spectrum would have differed significantly from that of wild-type in the
200 - 240 nm region.
In conclusion, we have developed protocols for purification of
wild-type VpAP, and of protease-intolerant site-directed variants. The
replacement of a C-terminal propeptide with a (His)6 adduct facilitates
very rapid isolation of the expressed polypeptide from contaminating
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proteolytic activity, from the supernatant of cultures of E. coli. Posttranslational processing of the purified polypeptide to the mature,
functional enzyme can be effected by traditional exposure to heat or
proteolytic activity or, for protease-intolerant variants, by an
apparently autocatalytic mechanism. Isolation of a final product that is
demonstrably devoid of the (His)6 construct is possible by a repeat
application to Co(II)-affinity resin. This advance will facilitate the
isolation and study of site-directed variants of VpAP with structurefunction relationship interest.
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